Pfizer said Monday its Covid-19 vaccine works for children ages 5 to 11 and that it will seek US authorisation for this age group soon -- a key step toward beginning vaccinations for youngsters.
The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration
DCGI on Friday granted permission to the Mukesh Ambani-owned Reliance Life Sciences to conduct phase-I clinical trial of its indigenous COVID-19 vaccine with certain conditions, sources said.
The UK's Chief Medical Officers will provide further advice on Covid-19 vaccination of young people aged between 12 to 15 years
To achieve herd immunity, studies have to be done on children, pharma major says
The cumulative Covid-19 vaccine doses administered in the country has exceeded 52.89 crore, the Union health ministry said on Thursday.
The cumulative COVID-19 vaccine doses administered in the country has crossed the landmark of 51 crore, the Union health ministry said on Monday. More than 49 lakh (49,06,273) doses have been administered on Monday, according to the 7 pm provisional report. The ministry said 26,66,611 vaccine doses were administered as first dose and 4,59,352 vaccine doses given as second dose in the age group 18-44 years on Monday. Cumulatively, 17,95,70,348 persons in the age group 18-44 years across all states and union territories have received their first dose and 1,24,91,475 have received their second dose since the start of the third phase of the vaccination drive. Five states -- Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar Pradesh -- have administered more than 1 crore cumulative doses of COVID-19 vaccine in the age group 18-44 years. Also, Andhra Pradesh, Assam, Chhattisgarh, Delhi, Haryana, Jharkhand, Kerala, Telangana, Himachal Pradesh, Odisha, Punjab, Uttarakhand and West
The Supreme Court on Monday sought responses from the Centre and others on a plea seeking directions for disclosure of data regarding clinical trials of Covid-19 vaccines.
An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years
This comes as the court said it would be a "disaster" if Covid-19 vaccines are administered, especially to children, without clinical trials
Clinical trial shows molnupiravir helps in early recovery in non-hospitalised Covid-19 patients
The phase-2 trials of the locally developed vaccine against Covid-19 started to be administered to volunteers in Istanbul, local media reported
The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials
The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission
The recruitment for the clinical trial of the country's first indigenously-developed COVID-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday. This will be followed by the clinical trial of children in the age-group of 2-6 years. The enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of Covaxin. "The recruitment process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday," Dr Sanjay Rai, Professor at the Centre for Community Medicine at the AIIMS, told PTI. The Drugs Controller General of India (DCGI) had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on May 12. The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years. In the tr
On track to make 100 mn doses per month by Q3 of 2021
Council of Scientific and Industrial Research (CSIR) along and Laxai Life Sciences Pvt. Ltd. on Sunday initiated Phase-II clinical trial for anti-helminitic drug Niclosamide for treatment of Covid-19.
Company says product helps treating mild coronavirus patients and reduces hospitalisation.
The clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
India's apex drug regulator has granted permission for conducting the phase II/III clinical trial of Bharat Biotech's Covaxin Covid-19 vaccine in the age group of 2 to 18 years